Zydus Lifesciences Limited (NSE:ZYDUSLIFE)
India · Delayed Price · Currency is INR 945.00
+8.30 (0.89%)
Nov 7, 2025, 3:29 PM IST
Zydus Lifesciences Revenue
Zydus Lifesciences had revenue of 61.23B INR in the quarter ending September 30, 2025, with 16.92% growth. This brings the company's revenue in the last twelve months to 244.94B, up 14.01% year-over-year. In the fiscal year ending March 31, 2025, Zydus Lifesciences had annual revenue of 232.42B with 18.90% growth.
Revenue (ttm)
244.94B
Revenue Growth
+14.01%
P/S Ratio
3.85
Revenue / Employee
8.77M
Employees
27,917
Market Cap
942.54B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2025 | 232.42B | 36.94B | 18.90% |
| Mar 31, 2024 | 195.47B | 23.10B | 13.40% |
| Mar 31, 2023 | 172.37B | 21.28B | 14.08% |
| Mar 31, 2022 | 151.10B | 7.06B | 4.90% |
| Mar 31, 2021 | 144.04B | 1.50B | 1.06% |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Sun Pharmaceutical Industries | 537.77B |
| Aurobindo Pharma | 320.25B |
| Cipla | 279.66B |
| Apollo Hospitals Enterprise | 225.51B |
| Biocon | 157.71B |
| Glenmark Pharmaceuticals | 134.56B |
| Alkem Laboratories | 133.04B |
| Mankind Pharma | 129.10B |
Zydus Lifesciences News
- 1 day ago - Zydus Lifesciences receives USFDA Orphan Drug Designation for Desidustat to treat beta-thalassemia - Business Upturn
- 2 days ago - Zydus Lifesciences receives ‘No Action Indicated’ classification from USFDA for Ahmedabad SEZ-II facility - Business Upturn
- 6 days ago - Zydus Lifesciences receives GST demand order worth Rs 74.23 crore; to challenge ruling - Business Upturn
- 7 days ago - Zydus and Lupin shares in focus today after Astellas raises Mirabegron guidance by 80% - Business Upturn
- 4 weeks ago - Zydus Lifesciences receives Health Canada approval for Liothyronine tablets 5 mcg and 25 mcg - Business Upturn
- 4 weeks ago - Zydus Lifesciences gets USFDA nod for Deflazacort oral suspension - Business Upturn
- 5 weeks ago - Zydus Lifesciences extends closing date for acquisition of Sterling Biotech’s API business - Business Upturn
- 6 weeks ago - Trump’s 100% tariffs on pharma: Sun Pharma, Biocon, Cipla & other pharmaceutical stocks tank; jitters on D-Street - The Times of India